BROR# | Age at enroll | Stage at DX | ER at DX | PR at DX | ER at enroll | PR at enroll | Time from DX to 1st met (months) | Disease sites at enrollment | Prior therapies for mets |
---|---|---|---|---|---|---|---|---|---|
01* | 54 | T3N3M0 | 99% 3+ | 40% 3+ | 99% 3+ | 99% 3+ | 23 | Bone, liver | 3-Endo, 3-Chemo |
02* | 59 | T2N2M0 | Positive | Positive | Negative | Negative | 152 | Bone, chest wall, non-regional lymph nodes | 1-Endo, 0-Chemo |
03 | 42 | T2N1M0 | 80% 2+ | 10% 2+ | Negative | Negative | 34 | Bone, chest wall | 3-Endo, 3-Chemo |
05 | 41 | T2N0M0 | Negative | Negative | Negative | Negative | 32 | Chest wall, lung | 1-Endo, 3-Chemo |
07* | 42 | T4N1M0 | Positive | Positive | 5% 1+ | 40% 1+ | 56 | Bone, liver, lung | 4-Endo, 3-Chemo |
08* | 59 | T1N1M0 | 50% 2+ | 50% 2+ | 25% 2+ | 40% 2+ | 77 | Bone, lung, retroperitoneal mass | 1-Endo, 2-Chemo |
09 | 30 | T3N1M0 | 0% | 0% | Negative | Negative | 22 | Lung | 0-Endo, 0-Chemo |
11 | 72 | T2N1MO | 30% 1+ | 30% 1+ | 5% 2+ | 85% 1+ | 27 | Chest wall | 0-Endo, 0-Chemo |
12 | 54 | T2NOMO | 6% | 0% | Negative | Negative | 17 | Lung | 0-Endo, 0-Chemo |
13* | 69 | T1N0M0 | Positive | Positive | 95% 3+ | 20% 3+ | 108 | Liver, non-regional lymph nodes | 3-Endo, 2-Chemo |
14* | 46 | T1N2M0 | 99% 3+ | 43% 2+ | 60% 3+ | 5% 1+ | 51 | Bone, chest wall | 2-Endo, 2-Chemo |
15* | 64 | TXN1M1 | 95% 3+ | 50% 2+ | 99% 3+ | 99% 3+ | Less than 1 | Bone, liver | 3-Endo, 1-Chemo |
16* | 63 | T3N2M0 | 99% | 90% | 85% 3+ | 40% 1+ | 72 | Peritoneum, pleura | 2-Endo, 3-Chemo |
17* | 49 | T4N3M0 | 60% | 40% | 80% 2+ | Negative | 37 | Bone, liver, non-regional lymph nodes, ovary, pleura | 2-Endo, 2-Chemo |
21 | 49 | T1N0M0 | Negative | Negative | Negative | Negative | 29 | Chest wall, lung | 0-Endo, 0-Chemo |
22* | 48 | T3N1M0 | 95% 3+ | 95% 3+ | 100% | < 1% | 47 | Chest wall, Lung | 1-Endo, 3-Chemo |